Tech rout led to another session of weakness on Wall Street on Tuesday as heavily-weighted Nvidia (NVA), peer AMD (AMD), and ...

After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...

Eli Lilly and Novo Nordisk are expected to price their new obesity pills in line with existing injections, as analysts cite ...

Recent advancements in Merck's (MRK) product portfolio, including the FDA's Breakthrough Therapy Designation for ifinatamab deruxtecan and several approvals of their flagship drug KEYTRUDA, are ...

The collaboration will explore RNA-based small molecule drug candidates aimed at neurological conditions where existing ...

The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 ...

Merck’s strong oncology gains, 4% yield, and low PEG ratio support its value case despite sector risks and patent concerns.

EdiMembre has spun off from Merck Group to commercialise its edible membrane tech for future foods, starting with whole-cut ...

New Jersey officials are eyeing several efforts, including a massive $500 million incentive program meant to entice more products to be "Made in NJ." ...

New research shows that people with dementia experience faster memory decline if they’re also diagnosed with inflammatory bowel disease (IBD).

Janux Therapeutics Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company that develops immunotherapies based on ...